Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rachel F Tyndale

Showing results (31-40 of 359) with videos related to

Pageof 36
Sort By:
Therapeutic Drug Monitoring|January 24, 2002
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behaviorRachel F Tyndale, Edward M Sellers
Molecular Neurobiology|September 28, 2021
Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone LevelsNicole Arguelles, Sharon Miksys, Rachel F Tyndale
The Journal of Pharmacology and Experimental Therapeutics|December 11, 2007
Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and miceEric C K Siu, Rachel F Tyndale
Annual Review of Pharmacology and Toxicology|January 11, 2007
Non-nicotinic therapies for smoking cessationEric C K Siu, Rachel F Tyndale
Journal of Neurogenetics|January 27, 2009
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymesRiju Ray, Rachel F Tyndale, Caryn Lerman
Molecular Pharmacology|December 13, 2006
Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 miceEric C K Siu, Rachel F Tyndale
Clinical Pharmacology and Therapeutics|March 1, 2005
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependenceViba Malaiyandi, Edward M Sellers, Rachel F Tyndale
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 10, 2006
In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatmentAnna M Lee, Jiang Yue, Rachel F Tyndale
Addiction Biology|December 22, 2017
Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesiaDouglas M McMillan, Sharon Miksys, Rachel F Tyndale
Pharmacogenomics|December 17, 2015
CYP2A6 genotyping methods and strategies using real-time and end point PCR platformsCatherine A Wassenaar, Qian Zhou, Rachel F Tyndale
Pageof 36

Showing results (31-40 of 359) with videos related to

Sort By:
Pageof 36
Therapeutic Drug Monitoring|January 24, 2002
Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behaviorRachel F Tyndale, Edward M Sellers
Molecular Neurobiology|September 28, 2021
Sex and Estrous Cycle Differences in Analgesia and Brain Oxycodone LevelsNicole Arguelles, Sharon Miksys, Rachel F Tyndale
The Journal of Pharmacology and Experimental Therapeutics|December 11, 2007
Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and miceEric C K Siu, Rachel F Tyndale
Annual Review of Pharmacology and Toxicology|January 11, 2007
Non-nicotinic therapies for smoking cessationEric C K Siu, Rachel F Tyndale
Journal of Neurogenetics|January 27, 2009
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymesRiju Ray, Rachel F Tyndale, Caryn Lerman
Molecular Pharmacology|December 13, 2006
Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 miceEric C K Siu, Rachel F Tyndale
Clinical Pharmacology and Therapeutics|March 1, 2005
Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependenceViba Malaiyandi, Edward M Sellers, Rachel F Tyndale
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 10, 2006
In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatmentAnna M Lee, Jiang Yue, Rachel F Tyndale
Addiction Biology|December 22, 2017
Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesiaDouglas M McMillan, Sharon Miksys, Rachel F Tyndale
Pharmacogenomics|December 17, 2015
CYP2A6 genotyping methods and strategies using real-time and end point PCR platformsCatherine A Wassenaar, Qian Zhou, Rachel F Tyndale
Pageof 36